Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.67
+0.18007.23%
Post-market: 2.670.0001+0.00%17:07 EDT
Volume:9.30M
Turnover:24.44M
Market Cap:2.36B
PE:-4.64
High:2.74
Open:2.51
Low:2.47
Close:2.49
Loading ...

Immunitybio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

Reuters
·
13 May

ImmunityBio Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
13 May

BUZZ-ImmunityBio rises on Q1 revenue beat

Reuters
·
12 May

Immunitybio Shares up 17.2% After Q1 Revenue Beat

THOMSON REUTERS
·
12 May

Sector Update: Health Care Stocks Advance Premarket Monday

MT Newswires Live
·
12 May

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 May

ImmunityBio Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
12 May

Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
12 May

ImmunityBio Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $16.52M Beat $16.02M Estimate

Benzinga
·
12 May

Press Release: ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

Dow Jones
·
12 May

Immunitybio Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
10 May

ImmunityBio Slides Following FDA Refusal-to-File Letter

Dow Jones
·
06 May

ImmunityBio refusal to file letter ‘surprising,’ says H.C. Wainwright

TIPRANKS
·
06 May

ImmunityBio Seeks Urgent FDA Meeting After Rejection for Bladder Cancer Therapy

MT Newswires Live
·
05 May

ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application

Dow Jones
·
05 May

BRIEF-ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency’S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May 2, 2025

Reuters
·
05 May

Immunitybio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a Sbla for Nmibc Bcg Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

THOMSON REUTERS
·
05 May

ImmunityBio Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Apr

ImmunityBio's Bladder Cancer Treatment Shows High Cystectomy Avoidance, Long-Term Response

MT Newswires Live
·
29 Apr